Cassy Workman

4.6k total citations · 1 hit paper
30 papers, 2.7k citations indexed

About

Cassy Workman is a scholar working on Virology, Infectious Diseases and Epidemiology. According to data from OpenAlex, Cassy Workman has authored 30 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Virology, 17 papers in Infectious Diseases and 7 papers in Epidemiology. Recurrent topics in Cassy Workman's work include HIV Research and Treatment (19 papers), HIV/AIDS drug development and treatment (17 papers) and HIV/AIDS Research and Interventions (11 papers). Cassy Workman is often cited by papers focused on HIV Research and Treatment (19 papers), HIV/AIDS drug development and treatment (17 papers) and HIV/AIDS Research and Interventions (11 papers). Cassy Workman collaborates with scholars based in Australia, United States and France. Cassy Workman's co-authors include Jean‐Michel Molina, Sorin Rugină, Janez Tomažič, Phillip Hay, E. Jägel-Guedes, Arlene R. Hughes, Alastair Benbow, Elizabeth J. Phillips, N J Fitch and Giampiero Carosi and has published in prestigious journals such as New England Journal of Medicine, The Lancet and The Journal of Experimental Medicine.

In The Last Decade

Cassy Workman

30 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

HLA-B*5701 Screening for Hypersensitivity to Abacavir

2008 1.2k citations S. Mallal, Elizabeth J. Phillips et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Cassy Workman Australia	16	1.3k	1.2k	563	556	514	30	2.7k
Corey Moore Australia	12	1.4k 1.1×	1.2k 1.0×	681 1.2×	658 1.2×	772 1.5×	19	2.9k
A. Martin Australia	19	500 0.4×	577 0.5×	355 0.6×	722 1.3×	783 1.5×	27	2.1k
N J Fitch United Kingdom	9	874 0.7×	691 0.6×	97 0.2×	550 1.0×	422 0.8×	14	2.1k
Janez Tomažič Slovenia	15	334 0.3×	542 0.5×	151 0.3×	560 1.0×	229 0.4×	51	1.7k
Margalida Rotger Switzerland	23	849 0.7×	1.1k 0.9×	272 0.5×	112 0.2×	168 0.3×	40	1.9k
Rui M. M. Victorino Portugal	25	1.1k 0.8×	422 0.4×	179 0.3×	129 0.2×	1.2k 2.4×	102	2.6k
Kirk D. Miller United States	22	1.3k 1.0×	1.3k 1.1×	757 1.3×	65 0.1×	313 0.6×	34	2.7k
Joaquin Valdes United States	16	887 0.7×	1.1k 0.9×	280 0.5×	54 0.1×	968 1.9×	31	2.6k
Margo Heath‐Chiozzi United States	13	801 0.6×	852 0.7×	158 0.3×	64 0.1×	206 0.4×	22	1.7k
Hartwig Klinker Germany	31	472 0.4×	1.1k 0.9×	266 0.5×	113 0.2×	148 0.3×	157	2.9k

Countries citing papers authored by Cassy Workman

Since Specialization

Citations

This map shows the geographic impact of Cassy Workman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cassy Workman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cassy Workman more than expected).

Fields of papers citing papers by Cassy Workman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cassy Workman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cassy Workman. The network helps show where Cassy Workman may publish in the future.

Co-authorship network of co-authors of Cassy Workman

This figure shows the co-authorship network connecting the top 25 collaborators of Cassy Workman. A scholar is included among the top collaborators of Cassy Workman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cassy Workman. Cassy Workman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Orchard, J., et al.. (2023). ENDEMIC COVID IS CONTRIBUTING TO SIGNIFICANT EXCESS CARDIAC MORTALITY. Journal of the American College of Cardiology. 81(8). 2361–2361. 1 indexed citations

Orchard, John, J. Orchard, Cassy Workman, & Rajesh Puranik. (2022). Prevention of the spread of respiratory viruses such as SARS-CoV-2 can also prevent cardiovascular deaths. Australian Journal of General Practice. 51(9). 732–734. 2 indexed citations

Cameron, Barbara, Carol Emerson, Cassy Workman, et al.. (2011). Alterations in Immune Function are Associated with Liver Enzyme Elevation in HIV and HCV Co-infection after Commencement of Combination Antiretroviral Therapy. Journal of Clinical Immunology. 31(6). 1079–1083. 6 indexed citations

Cahn, Pedro, Jan Fourie, Beatriz Grinsztejn, et al.. (2011). Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients. AIDS. 25(7). 929–939. 75 indexed citations

Mills, Anthony, Mark Nelson, Dushyantha Jayaweera, et al.. (2009). Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS. 23(13). 1679–1688. 199 indexed citations

Kakuda, Thomas N., Cassy Workman, Keikawus Arastéh, et al.. (2008). Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients. Antiviral Therapy. 13(5). 655–661. 27 indexed citations

Bánhegyi, Dénes, Christine Katlama, Cláudio Da Cunha, et al.. (2008). Phase III TITAN week 96 final analysis: efficacy/safety of darunavir/r (DRV/r) vs. lopinavir/r (LPV/r) in LPV-naïve, treatment-experienced patients. Journal of the International AIDS Society. 11(S1). 4 indexed citations

Mallal, S., Elizabeth J. Phillips, Giampiero Carosi, et al.. (2008). HLA-B*5701 Screening for Hypersensitivity to Abacavir. New England Journal of Medicine. 358(6). 568–579. 1185 indexed citations breakdown →

Emery, Sean, Anthony D. Kelleher, Cassy Workman, et al.. (2007). Influence of IFNγ Co-Expression on the Safety and Antiviral Efficacy of Recombinant Fowlpox Virus HIV Therapeutic Vaccines Following Interruption of Antiretroviral Therapy. Human Vaccines. 3(6). 260–267. 24 indexed citations

10.

Dyer, Wayne B., et al.. (2007). Drug Resistance and Viral Evolution in Plasma and Peripheral Blood Cells During Structured Treatment Interruption (STI) and Non-Interrupted HAART. Current HIV Research. 5(2). 235–250. 15 indexed citations

11.

Gathe, Joseph, David A. Cooper, Charles Farthing, et al.. (2006). Efficacy of the Protease Inhibitors Tipranavir plus Ritonavir in Treatment-Experienced Patients: 24-Week Analysis from the RESIST-1 Trial. Clinical Infectious Diseases. 43(10). 1337–1346. 67 indexed citations

12.

Emery, Sean, Cassy Workman, Rebekah Puls, et al.. (2005). Randomised, Placebo-Controlled, Phase I/IIa Evaluation of the Safety and Immunogenicity of Fowlpox Virus Expressing HIV gag-pol and Interferon-? in HIV-1 Infected Subjects. Human Vaccines. 1(6). 232–238. 22 indexed citations

13.

Martin, Allison, Don Smith, Andrew Carr, et al.. (2004). Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir. AIDS. 18(7). 1029–1036. 240 indexed citations

14.

Carr, Andrew, Cassy Workman, Dianne Carey, et al.. (2004). No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. The Lancet. 363(9407). 429–438. 186 indexed citations

15.

Dyer, Wayne B., Harmjan Kuipers, Marcel W. Coolen, et al.. (2002). Correlates of Antiviral Immune Restoration in Acute and Chronic HIV Type 1 Infection: Sustained Viral Suppression and Normalization of T Cell Subsets. AIDS Research and Human Retroviruses. 18(14). 999–1010. 13 indexed citations

16.

Workman, Cassy, et al.. (2001). Changes in HIV‐1 viral load trends with highly active antiretroviral therapy. The Medical Journal of Australia. 174(4). 199–200. 1 indexed citations

17.

Kelleher, Anthony D., Edward C. Holmes, Rachel Allen, et al.. (2001). Clustered Mutations in HIV-1 Gag Are Consistently Required for Escape from Hla-B27–Restricted Cytotoxic T Lymphocyte Responses. The Journal of Experimental Medicine. 193(3). 375–386. 360 indexed citations

18.

Jin, Xia, Marie‐Ange Demoitié, Sean M. Donahoe, et al.. (2000). High Frequency of Cytomegalovirus‐Specific Cytotoxic T‐Effector Cells in HLA‐A*0201–Positive Subjects during Multiple Viral Coinfections. The Journal of Infectious Diseases. 181(1). 165–175. 58 indexed citations

19.

Dyer, Wayne B., et al.. (2000). Molecular evidence for drug-induced compartmentalization of HIV-1 quasispecies in a patient with periodic changes to HAART. AIDS. 14(15). 2265–2272. 34 indexed citations

20.

Oelrichs, Robert, Cassy Workman, Tiina Laukkanen, Francine E. McCutchan, & Nicholas J. Deacon. (1998). Sequence Note : A Novel Subtype A/G/J Recombinant Full-Length HIV Type 1 Genome from Burkina Faso. AIDS Research and Human Retroviruses. 14(16). 1495–1500. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact